Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Estrella Immunopharma, Inc. (ESLA) had Return on Tangible Equity of 114.93% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-2.10M |
|
-- |
|
-- |
|
$2.10M |
|
$-2.10M |
|
-- |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
$-2.10M |
|
36.19M |
|
36.19M |
|
$-0.06 |
|
$-0.06 |
|
| Balance Sheet Financials | |
$0.94M |
|
-- |
|
$1.50M |
|
$2.44M |
|
$4.28M |
|
-- |
|
-- |
|
$4.28M |
|
$-1.83M |
|
$-1.83M |
|
$-1.83M |
|
36.17M |
|
| Cash Flow Statement Financials | |
$-0.47M |
|
-- |
|
$-0.03M |
|
$0.92M |
|
$0.42M |
|
$-0.50M |
|
$0.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
114.93% |
|
|
Return on Tangible Equity |
114.93% |
-86.09% |
|
114.93% |
|
$-0.05 |
|
$-0.01 |
|
$-0.01 |
|